BNP Paribas Asset Management
ANIP icon

BNP Paribas Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

BNP Paribas Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6K Buy
249
+1
+0.4% +$80 ﹤0.01% 2041
2026
Q1 		$19.1K Sell
248
-613
-71% -$47.8K ﹤0.01% 2050
2025
Q4 		$68K Buy
+861
New +$74.5K ﹤0.01% 1574
2025
Q3 		– Sell
-129
Closed -$8K – 1871
2025
Q2 		$8K Buy
+129
New +$8.4K ﹤0.01% 1833

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BNP Paribas Asset Management's ANIP Position: Q2 2026 in Review

BNP Paribas Asset Management increased its ANI Pharmaceuticals (ANIP) stake by 0.4% in Q2 2026, buying an estimated $80 and bringing the position to 249 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2041.

BNP Paribas Asset Management first reported a position in ANIP in Q2 2025 and has held it in 4 quarters since. The position peaked at $68K in Q4 2025. 283 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • BNP Paribas Asset Management held 249 shares of ANI Pharmaceuticals worth $20.6K as of Q2 2026.
  • BNP Paribas Asset Management bought 1 ANI Pharmaceuticals share in Q2 2026, an estimated $80.
  • ANI Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2041 holding.
  • BNP Paribas Asset Management first reported a position in ANI Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's ANI Pharmaceuticals position peaked at $68K in Q4 2025.
  • 283 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.